Evaluation of the inhibitory effects of antihypertensive drugs on human carboxylesterase in vitro

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 6, 2013, Pages 468-474

  Yanjiao, Xu ^a   Chengliang, Zhang ^a   Xiping, Li ^a   Tao, Wu ^a   Xiuhua, Ren ^a   Dong, Liu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antihypertensive drugs; Carboxylesterase; Drug interaction; Enzyme kinetics; Inhibition; Microsomes; Prodrugs; Toxicology

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CANDESARTAN; CARBOXYLESTERASE; CARBOXYLESTERASE 1A1; CARBOXYLESTERASE 2; CILNIDIPINE; DILTIAZEM; FELODIPINE; HYDROCHLOROTHIAZIDE; IMIDAPRIL; IRINOTECAN; LACIDIPINE; LOSARTAN; METOPROLOL; NICARDIPINE; NIFEDIPINE; NITRENDIPINE; PROPRANOLOL; TELMISARTAN; TIMOLOL; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER CELL CULTURE; LIVER MICROSOME;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; CARBOXYLESTERASE; DILTIAZEM; DRUG INTERACTIONS; HUMANS; IMIDAZOLIDINES; LIVER; NITRENDIPINE; VERAPAMIL;

EID: 84890626748     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-143     Document Type: Article

References (25)

1. Fukami, T., Nakajima, M., Maruichi, T., Takahashi, S., Takamiya, M., Aoki, Y., McLeod, H. L. and Yokoi, T.: Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet. Genomics, 18: 911-920 (2008).
2. Hosokawa, M., Furihata, T., Yaginuma, Y., Yamamoto, N., Koyano, N., Fujii, A., Nagahara, Y., Satoh, T. and Chiba, K.: Genomic structure and transcriptional regulation of the rat, mouse, and human carboxylesterase genes. Drug Metab. Rev., 39: 1-15 (2007).
3. Maruichi, T., Fukami, T., Nakajima, M. and Yokoi, T.: Transcriptional regulation of human carboxylesterase 1A1 by nuclear factor-erythroid 2 related factor 2 (Nrf2). Biochem. Pharmacol., 79: 288-295 (2010).
4. Satoh, T., Taylor, P., Bosron, W. F., Sanghani, S. P., Hosokawa, M. and La Du, B. N.: Current progress on esterases: from molecular structure to function. Drug Metab. Dispos., 30: 488-493 (2002).
5. Imai, T., Taketani, M., Shii, M., Hosokawa, M. and Chiba, K.: Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab. Dispos., 34: 1734-1741 (2006).
6. Taketani, M., Shii, M., Ohura, K., Ninomiya, S. and Imai, T.: Carboxylesterase in the liver and small intestine of experimental animals and human. Life Sci., 81: 924-932 (2007).
7. Khanna, R., Morton, C. L., Danks, M. K. and Potter, P. M.: Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res., 60: 4725-4728 (2000).
8. Imai, T.: Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab. Pharmacokinet., 21: 173-185 (2006).
9. Goel, S., Desai, K., Karri, S., Gollamudi, R., Chaudhary, I., Bulgaru, A., Kaubisch, A., Goldberg, G., Einstein, M., Camacho, F., Baker, S. and Mani, S.: Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. Invest. New Drugs., 25: 237-245 (2007).
10. Zeni, C. P., Tramontina, S., Ketzer, C. R., Pheula, G. F. and Rohde, L. A.: Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. J. Child Adolesc. Psychopharmacol., 19: 553-561 (2009).
11. Zhu, H. J., Appel, D. I., Peterson, Y. K., Wang, Z. and Markowitz, J. S.: Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. Toxicology, 270: 59-65 (2010).
12. Fukami, T., Takahashi, S., Nakagawa, N., Maruichi, T., Nakajima, M. and Yokoi, T.: In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Drug Metab. Dispos., 38: 2173-2178 (2010).
13. Takahashi, S., Katoh, M., Saitoh, T., Nakajima, M. and Yokoi, T.: Allosteric kinetics of human carboxylesterase 1: species differences and interindividual variability. J. Pharm. Sci., 97: 5434-5445 (2008).
14. Humerickhouse, R., Lohrbach, K., Li, L., Bosron, W. F. and Dolan, M. E.: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res., 60: 1189-1192 (2000).
15. Zhang, C. L., Gao, P., Yin, W. F., Xu, Y. J., Xiang, D. C. and Liu, D.: Dexamethasone Regulates Differential Expression of Carboxylesterase1 and Carboxylesterase 2 through Activation of Nuclear Receptors. J. Huazhong. Univ. Sci. Technolog. Med. Sci., 32: 798-805 (2012).
16. Liu, D., Gao, J., Zhang, C. L., Xiang, D. C. and Gao, P.: Determination of irinotecan (CPT-11) and its active metabolite SN-38 in rat plasma by high-performance liquid chromatography. Chin. J. Pharm. Anal., 31: 625-628 (2011).
17. Watanabe, A., Fukami, T., Nakajima, M., Takamiya, M., Aoki, Y. and Yokoi, T.: Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. Drug Metab. Dispos., 37: 1513-1520 (2009).
18. Takahashi, S., Katoh, M., Saitoh, T., Nakajima, M. and Yokoi, T.: Different inhibitory effects in rat and human carboxylesterases. Drug Metab. Dispos., 37: 956-961 (2009).
19. Hatfield, M. J. and Potter, P. M.: Carboxylesterase inhibitors. Expert. Opin. Ther. Pat., 21: 1159-1171 (2011).
20. Ma, B., Prueksaritanont, T. and Lin, J. H.: Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab. Dispos., 28: 125-130 (2000).
21. Pershing, L. K. and Franklin, M. R.: Cytochrome P-450 metabolicintermediate complex formation and induction by macrolide antibiotics; a new class of agents. Xenobiotica, 12: 687-699 (1982).
22. Bensoussan, C., Delaforge, M. and Mansuy, D.: Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem. Pharmacol., 49: 591-602 (1995).
23. Schwer, H., Langmann, T., Daig, R., Becker, A., Aslanidis, C. and Schmitz, G.: Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver. Biochem. Biophys. Res. Commun., 233: 117-120 (1997).
24. Maxwell, D. M. and Brecht, K. M.: Carboxylesterase: specificity and spontaneous reactivation of an endogenous scavenger for organophosphorus compounds. J. Appl. Toxicol., 21 Suppl 1: S103-S107 (2001).
25. Ross, M. K. and Crow, J. A.: Human carboxylesterases and their role in xenobiotic and endobiotic metabolism. J. Biochem. Mol. Toxicol., 21: 187-196 (2007).